Nuveen LLC Acquires Shares of 440,561 Vanda Pharmaceuticals Inc. $VNDA

Nuveen LLC bought a new stake in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 440,561 shares of the biopharmaceutical company’s stock, valued at approximately $2,022,000. Nuveen LLC owned 0.75% of Vanda Pharmaceuticals as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Quantinno Capital Management LP purchased a new stake in shares of Vanda Pharmaceuticals during the fourth quarter worth $48,000. Linden Thomas Advisory Services LLC acquired a new position in Vanda Pharmaceuticals in the 1st quarter worth about $49,000. Virtu Financial LLC acquired a new position in Vanda Pharmaceuticals in the 1st quarter worth about $72,000. ProShare Advisors LLC raised its stake in shares of Vanda Pharmaceuticals by 32.4% during the 4th quarter. ProShare Advisors LLC now owns 18,815 shares of the biopharmaceutical company’s stock worth $90,000 after purchasing an additional 4,599 shares in the last quarter. Finally, Bailard Inc. bought a new stake in shares of Vanda Pharmaceuticals in the 1st quarter valued at approximately $103,000. 88.14% of the stock is currently owned by hedge funds and other institutional investors.

Vanda Pharmaceuticals Stock Up 0.6%

VNDA stock opened at $4.73 on Friday. The business’s 50-day simple moving average is $4.63 and its 200 day simple moving average is $4.53. Vanda Pharmaceuticals Inc. has a twelve month low of $3.81 and a twelve month high of $5.55. The company has a market cap of $279.50 million, a PE ratio of -4.19 and a beta of 0.72.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.12). The firm had revenue of $52.59 million for the quarter, compared to the consensus estimate of $54.77 million. Vanda Pharmaceuticals had a negative net margin of 32.90% and a negative return on equity of 12.89%. Vanda Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current year.

Insider Transactions at Vanda Pharmaceuticals

In other news, Director Stephen Ray Mitchell sold 7,000 shares of the stock in a transaction on Friday, June 13th. The shares were sold at an average price of $4.59, for a total value of $32,130.00. Following the completion of the transaction, the director owned 97,082 shares in the company, valued at approximately $445,606.38. This represents a 6.73% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 10.00% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on VNDA. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Vanda Pharmaceuticals in a research note on Thursday, August 21st. Cantor Fitzgerald restated an “overweight” rating and set a $13.00 price target on shares of Vanda Pharmaceuticals in a report on Wednesday, May 14th. Finally, Wall Street Zen cut shares of Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Saturday, August 2nd. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Buy rating to the stock. According to MarketBeat, the company has an average rating of “Strong Buy” and an average price target of $16.50.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.